Pipeline
Addressing life-threatening, difficult-to-treat solid tumors
A2 Bio’s Pipeline
Our rich pipeline includes one clinical and three pre-clinical programs with different clinically validated solid tumor targets. Tmod™ technology is modular, flexible and compatible with many types of immune cells, as well as manufacturing platforms. A2 Bio is focusing on the use of T cells for our initial pipeline.
Our pipeline
PROGRAM
ACTIVATOR
BLOCKER
INDICATIONS
COMMERCIAL RIGHTS
DISCOVERY
IND-ENABLING
PHASE 1
PHASE 2
AUTOLOGOUS
PROGRAM
ACTIVATOR
CEA
BLOCKER
HLA-A*02
INDICATIONS
Colorectal, Lung and Pancreatic
COMMERCIAL RIGHTS
PROGRAM
ACTIVATOR
MSLN
BLOCKER
HLA-A*02
INDICATIONS
Ovarian, Mesothelioma, Pancreatic, Colorectal, Lung
COMMERCIAL RIGHTS
ALLOGENEIC
PROGRAM
ACTIVATOR
UNDISCLOSED
BLOCKER
INDICATIONS
COMMERCIAL RIGHTS
PROGRAM
ACTIVATOR
UNDISCLOSED
BLOCKER
INDICATIONS
COMMERCIAL RIGHTS
PROGRAM
ACTIVATOR
UNDISCLOSED
BLOCKER
INDICATIONS
COMMERCIAL RIGHTS
Programs
Our two lead programs are autologous, followed by three allogeneic candidates.
About A2B530
A2B530 is a Tmod™ chimeric antigen receptor (CAR) T cell therapy targeting tumors that express carcinoembryonic antigen (CEA) but lack the HLA-A*02 antigen. A2B530 is being studied in our clinical trial EVEREST-1. EVEREST-1 is designed to evaluate patients with recurrent, unresectable, locally advanced, or metastatic non-small cell lung cancer (NSCLC), colorectal cancer (CRC), and pancreatic cancer (PANC), which are associated with CEA expression.
About A2B694
A2B694 is a Tmod™ chimeric antigen receptor (CAR) T cell therapy targeting tumors that express mesothelin (MSLN) but lack the HLA-A*02 antigen. We intend to evaluate A2B694 in a clinical trial, studying patients with recurrent, unresectable, locally advanced, or metastatic non-small cell lung cancer (NSCLC), colorectal cancer (CRC), pancreatic cancer (PANC), ovarian cancer (OVCA) and mesothelioma, which are associated with MSLN expression.
The modularity of the Tmod™ platform enables vast pipeline expansion opportunities. Additional therapies can be created by varying activator and blocker combinations.